Vemurafenib
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
VIIth nerve paralysis
|
VIIth nerve paralysis
|
common
|
|
x
|
x
|
|
Dermatitis
|
Rash
|
postmarketing, 0% - 52%
|
|
x
|
x
|
x
|
Rash
|
Rash
|
postmarketing, 0% - 52%
|
|
x
|
x
|
x
|
Asthenia
|
Fatigue
|
postmarketing, 2% - 54%
|
|
x
|
x
|
x
|
Asthenia
|
postmarketing, 0% - 11%
|
|
x
|
x
|
x
|
Fatigue
|
Fatigue
|
postmarketing, 2% - 54%
|
|
x
|
x
|
x
|
Gamma-glutamyltransferase increased
|
Gamma-glutamyltransferase increased
|
0% - 15%
|
|
x
|
x
|
|
Arthralgia
|
Arthralgia
|
postmarketing, 1% - 67%
|
|
x
|
x
|
x
|
Musculoskeletal discomfort
|
Arthralgia
|
postmarketing, 1% - 67%
|
|
x
|
x
|
x
|
Myalgia
|
postmarketing, 0% - 24%
|
|
x
|
x
|
x
|
Photosensitivity reaction
|
Photosensitivity reaction
|
postmarketing, 0% - 49%
|
|
x
|
x
|
x
|
Photosensitivity
|
postmarketing
|
|
x
|
x
|
x
|
Sunburn
|
postmarketing, 0% - 14%
|
|
x
|
x
|
x
|
Dizziness
|
Dizziness
|
postmarketing, common
|
|
|
x
|
x
|
Erythema nodosum
|
Erythema nodosum
|
postmarketing, common
|
|
x
|
x
|
x
|
Nervous system disorder
|
Nervous system disorder
|
postmarketing, common
|
|
x
|
x
|
x
|
Keratosis pilaris
|
Keratosis pilaris
|
postmarketing, common
|
|
x
|
x
|
x
|
Body temperature increased
|
Body temperature increased
|
postmarketing, 1% - 19%
|
|
x
|
x
|
x
|
Nausea
|
Nausea
|
postmarketing, 2% - 43%
|
|
x
|
x
|
x
|
Pain in extremity
|
Pain in extremity
|
postmarketing, 0% - 18%
|
|
x
|
x
|
x
|
Vomiting
|
Vomiting
|
postmarketing, 1% - 26%
|
|
x
|
x
|
x
|
Rash maculo-papular
|
Rash maculo-papular
|
postmarketing, 0% - 21%
|
|
x
|
x
|
x
|
Pruritus
|
Pruritus
|
postmarketing, 0% - 30%
|
|
x
|
x
|
x
|
Alopecia
|
Alopecia
|
postmarketing, 0% - 45%
|
|
x
|
x
|
x
|
Back pain
|
Back pain
|
postmarketing, 1% - 11%
|
|
x
|
x
|
x
|
Constipation
|
Constipation
|
postmarketing, 0% - 24%
|
|
x
|
x
|
x
|
Diarrhoea
|
Diarrhoea
|
postmarketing, 1% - 29%
|
|
x
|
x
|
x
|
Headache
|
Headache
|
postmarketing, 0% - 27%
|
|
x
|
x
|
x
|
Seborrhoeic keratosis
|
Seborrhoeic keratosis
|
postmarketing, 0% - 14%
|
|
x
|
x
|
x
|
Actinic keratosis
|
postmarketing, 0% - 17%
|
|
x
|
x
|
x
|
Musculoskeletal pain
|
Musculoskeletal pain
|
postmarketing, 0% - 11%
|
|
x
|
x
|
x
|
Oedema peripheral
|
Oedema peripheral
|
postmarketing, 0% - 23%
|
|
x
|
x
|
x
|
Myalgia
|
Myalgia
|
postmarketing, 0% - 24%
|
|
x
|
x
|
x
|
Hyperkeratosis
|
Hyperkeratosis
|
postmarketing, 0% - 28%
|
|
x
|
x
|
x
|
Keratosis
|
postmarketing
|
|
|
x
|
x
|
Decreased appetite
|
Decreased appetite
|
postmarketing, 0% - 21%
|
|
x
|
x
|
x
|
Anaphylactic shock
|
Anaphylactic shock
|
postmarketing
|
|
|
|
x
|
Arthritis
|
Arthritis
|
postmarketing
|
|
x
|
x
|
x
|
Basal cell carcinoma
|
Basal cell carcinoma
|
postmarketing
|
|
x
|
x
|
x
|
Infection
|
Infection
|
postmarketing
|
|
x
|
x
|
x
|
Connective tissue disorder
|
Connective tissue disorder
|
postmarketing
|
|
x
|
|
x
|
Cough
|
Cough
|
postmarketing, 0% - 12%
|
|
x
|
x
|
x
|
Cyst
|
Cyst
|
postmarketing
|
|
x
|
x
|
x
|
Dysgeusia
|
Dysgeusia
|
postmarketing, 0% - 14%
|
|
x
|
x
|
x
|
Eosinophilia
|
Eosinophilia
|
postmarketing
|
|
x
|
x
|
x
|
Toxic epidermal necrolysis
|
Toxic epidermal necrolysis
|
postmarketing, common
|
|
x
|
x
|
x
|
Eye disorder
|
Eye disorder
|
postmarketing
|
|
x
|
x
|
x
|
Folliculitis
|
Folliculitis
|
postmarketing
|
|
x
|
x
|
x
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
postmarketing
|
|
x
|
|
x
|
Cardiac disorder
|
Cardiac disorder
|
postmarketing
|
|
x
|
x
|
x
|
Hypersensitivity
|
Hypersensitivity
|
postmarketing
|
|
x
|
x
|
x
|
Hypotension
|
Hypotension
|
postmarketing
|
|
|
x
|
x
|
Keratoacanthoma
|
Keratoacanthoma
|
postmarketing
|
|
|
x
|
x
|
Actinic keratosis
|
Actinic keratosis
|
postmarketing, 0% - 17%
|
|
x
|
x
|
x
|
Chronic myelomonocytic leukaemia
|
Chronic myelomonocytic leukaemia
|
postmarketing
|
|
x
|
x
|
x
|
Mediastinal disorder
|
Mediastinal disorder
|
postmarketing
|
|
x
|
x
|
x
|
Malignant melanoma
|
Malignant melanoma
|
postmarketing
|
|
|
|
x
|
Neoplasm
|
Neoplasm
|
postmarketing
|
|
x
|
x
|
x
|
Neuropathy peripheral
|
Neuropathy peripheral
|
postmarketing
|
|
x
|
x
|
x
|
Polyp
|
Polyp
|
postmarketing
|
|
x
|
x
|
x
|
Retinal vein occlusion
|
Retinal vein occlusion
|
postmarketing
|
|
x
|
x
|
x
|
Erythema multiforme
|
Stevens-Johnson syndrome
|
postmarketing, common
|
|
x
|
x
|
x
|
Stevens-Johnson syndrome
|
Stevens-Johnson syndrome
|
postmarketing, common
|
|
x
|
x
|
x
|
Erythema
|
Erythema
|
postmarketing, 0% - 14%
|
|
x
|
|
x
|
Uveitis
|
Uveitis
|
postmarketing
|
|
|
x
|
x
|
Angiopathy
|
Angiopathy
|
postmarketing
|
|
x
|
x
|
x
|
Vasculitis
|
Vasculitis
|
postmarketing
|
|
x
|
x
|
x
|
Skin papilloma
|
Common wart
|
postmarketing
|
|
|
x
|
x
|
Skin papilloma
|
postmarketing, 0% - 30%
|
|
x
|
x
|
x
|
Weight decreased
|
Weight decreased
|
postmarketing
|
|
|
x
|
x
|
Dry skin
|
Dry skin
|
postmarketing, 0% - 19%
|
|
x
|
x
|
x
|
Malnutrition
|
Malnutrition
|
postmarketing
|
|
x
|
x
|
x
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing, common
|
|
x
|
x
|
x
|
Paralysis
|
Nerve paralysis
|
postmarketing
|
|
|
|
x
|
Metastatic malignant melanoma
|
Metastatic melanoma
|
postmarketing
|
|
|
|
x
|
Rash generalised
|
Rash generalised
|
postmarketing
|
|
|
|
x
|
Squamous cell carcinoma of skin
|
Squamous cell carcinoma of skin
|
postmarketing
|
|
|
x
|
x
|
Infestation
|
Infestation NOS
|
postmarketing
|
|
x
|
x
|
x
|
Electrocardiogram QT prolonged
|
Electrocardiogram QT corrected interval prolonged
|
postmarketing
|
|
|
x
|
x
|
Rash papular
|
Rash papular
|
postmarketing, 0% - 13%
|
|
x
|
x
|
x
|
Atrial fibrillation
|
Atrial fibrillation
|
|
|
x
|
x
|
|
Neoplasm malignant
|
Neoplasm malignant
|
|
|
x
|
|
|
Squamous cell carcinoma
|
Squamous cell carcinoma
|
|
|
|
x
|
|
Palmar erythema
|
Palmar erythema
|
|
|
|
x
|
|
Sunburn
|
Sunburn
|
postmarketing, 0% - 14%
|
|
x
|
x
|
x
|
Hepatotoxicity
|
Hepatotoxicity
|
|
|
x
|
|
|
Oropharyngeal squamous cell carcinoma
|
Oropharyngeal squamous cell carcinoma
|
|
|
x
|
|
|
Chills
|
Rigors
|
|
|
|
x
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 64 |
Source: | FDA Structured Product Label |
---|
Side effects: | 70 |
Source: | medicines.org.au |
---|
Side effects: | 72 |
Source: | EMA |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|